{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:04:17Z","timestamp":1791515057603,"version":"4.3.4"},"reference-count":24,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,6,29]]},"DOI":"10.2967\/jnumed.126.272714","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:20:16Z","timestamp":1785421216000},"page":"jnumed.126.272714","source":"Crossref","is-referenced-by-count":2,"title":["A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA)"],"prefix":"10.2967","author":[{"given":"Sobia","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Hioki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Luckerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026073007200930000_jnumed.126.272714v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026073007200930000_jnumed.126.272714v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026073007200930000_jnumed.126.272714v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026073007200930000_jnumed.126.272714v1.4","doi-asserted-by":"crossref","first-page":"S1630","DOI":"10.1016\/j.annonc.2025.09.105","article-title":"LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21 [abstract]","volume":"36(suppl 2)","author":"Chi","year":"2025","journal-title":"Ann Oncol."},{"key":"2026073007200930000_jnumed.126.272714v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.014"},{"key":"2026073007200930000_jnumed.126.272714v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2026073007200930000_jnumed.126.272714v1.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026073007200930000_jnumed.126.272714v1.8","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2024.42.16_suppl.5074","article-title":"Final results of a phase I\/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clinl Oncol."},{"key":"2026073007200930000_jnumed.126.272714v1.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264104"},{"key":"2026073007200930000_jnumed.126.272714v1.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262552"},{"key":"2026073007200930000_jnumed.126.272714v1.11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41392-023-01639-6","article-title":"Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling","volume":"8","author":"Macedo-Silva","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"2026073007200930000_jnumed.126.272714v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256263"},{"key":"2026073007200930000_jnumed.126.272714v1.13","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-023-01857-y"},{"key":"2026073007200930000_jnumed.126.272714v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2026073007200930000_jnumed.126.272714v1.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265242"},{"key":"2026073007200930000_jnumed.126.272714v1.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"2026073007200930000_jnumed.126.272714v1.17","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026073007200930000_jnumed.126.272714v1.18","doi-asserted-by":"crossref","first-page":"5247153","DOI":"10.1155\/2018\/5247153","article-title":"177Lu-DOTA-HYNIC-Lys(Nal)-urea-Glu: biokinetics, dosimetry, and evaluation in patients with advanced prostate cancer","volume":"2018","author":"Santos-Cuevas","year":"2018","journal-title":"Contrast Media Mol Imaging."},{"key":"2026073007200930000_jnumed.126.272714v1.19","doi-asserted-by":"crossref","first-page":"e1321168","DOI":"10.1080\/23723556.2017.1321168","article-title":"PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression","volume":"4","author":"Caromile","year":"2017","journal-title":"Mol Cell Oncol."},{"key":"2026073007200930000_jnumed.126.272714v1.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2026073007200930000_jnumed.126.272714v1.21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171052"},{"key":"2026073007200930000_jnumed.126.272714v1.22","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026073007200930000_jnumed.126.272714v1.23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/cancers12020388","article-title":"DNA damage in blood leukocytes of prostate cancer patients undergoing PET\/CT examinations with [68Ga]Ga-PSMA I&T","volume":"12","author":"Schumann","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2026073007200930000_jnumed.126.272714v1.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:20:17Z","timestamp":1785421217000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":24,"alternative-id":["10.2967\/jnumed.126.272714"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272714","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}